All articles tagged with #cuatsm
A copper-containing drug Cu(ATSM) boosted brain P-glycoprotein pumps, increased clearance of amyloid-beta by about 42%, and improved spatial memory by about 44% over 56 days in Alzheimer's-model mice, suggesting a potential preclinical approach to restore brain waste clearance, though human trials and safety assessments remain essential.
Monash University researchers report in ACS Chemical Neuroscience that the copper compound Cu(ATSM) strengthens the brain's waste-clearing system by boosting P-glycoprotein pumps at the blood-brain barrier in an Alzheimer's model, reducing amyloid-beta by 42% and improving spatial memory by about 44% over 56 days, pointing to a therapy for neurovascular dysfunction; Cu(ATSM) has safety data from other neurological conditions, potentially speeding human testing, though exact clearance pathways and microglial involvement require further study.
Monash University researchers used Cu(ATSM), a copper-delivery compound, to repair the brain’s blood–brain barrier by increasing the P-glycoprotein clearance pumps, which reduced toxic amyloid-beta by about 42% and improved long-term spatial memory by roughly 44% in an APP/PS1 mouse model over 56 days, suggesting copper-based biometal therapy could be a promising route for early symptomatic Alzheimer's disease with potential for quicker human testing due to prior safety evaluations; future work aims to map the precise clearance mechanisms and pathways.